Patents Issued in July 4, 2017
  • Patent number: 9693951
    Abstract: An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 4, 2017
    Assignee: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
    Inventors: Charles David Ogilvy Potter, Shohre Nabahi
  • Patent number: 9693952
    Abstract: An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: July 4, 2017
    Assignee: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
    Inventors: Charles David Ogilvy Potter, Shohre Nabahi
  • Patent number: 9693953
    Abstract: The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: July 4, 2017
    Inventors: Janet A. Chollet, Fred H. Mermelstein, Bernadette Klamerus
  • Patent number: 9693954
    Abstract: The invention provides methods and compositions for local manipulation of regenerative processes via exogenous factor delivery.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: July 4, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: David J. Mooney, William W. Yuen, Praveen Arany
  • Patent number: 9693955
    Abstract: The invention relates to aerosolized and humidified particles comprising a therapeutically active substance which can be obtained by suspending dry inhalable particles in a carrier gas, adding water vapor and causing condensation of water on the particles. The invention further relates to methods to generate these particles, and apparatus useful to carry out such methods.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: July 4, 2017
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Daniela Rahmel, Friedemann Taut, Christian De Muynck, Markus Rast, Peter Iwatschenko, Gerhard Pohlmann, Wolfgang Koch, Horst Windt
  • Patent number: 9693956
    Abstract: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: July 4, 2017
    Inventor: Bernd G. Seigfried
  • Patent number: 9693957
    Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: July 4, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie A. Kramer, Christopher Y. Poon
  • Patent number: 9693958
    Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 4, 2017
    Assignee: Cureport, Inc.
    Inventor: De-Min Zhu
  • Patent number: 9693959
    Abstract: A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of a) providing a composition comprising a polysaccharide derivative and a controlled amount of a liquid diluent, based on the dry weight of the polysaccharide derivative, b) subjecting the composition to a dry-grinding operation to provide a dry-ground polysaccharide derivative, and c) incorporating the dry-ground polysaccharide derivative and an active ingredient into a dosage form.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: July 4, 2017
    Inventors: Yvonne M. Goerlach-Doht, Juergen Hermanns, Nicholas S. Grasman
  • Patent number: 9693960
    Abstract: A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of a) providing a composition comprising a polysaccharide derivative and a controlled amount of a liquid diluent, based on the dry weight of the polysaccharide derivative, b) subjecting the composition to a dry-grinding operation to provide a dry-ground polysaccharide derivative, and c) incorporating the dry-ground polysaccharide derivative and an active ingredient into a dosage form.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: July 4, 2017
    Inventors: Yvonne M. Goerlach-Doht, Juergen Hermanns, Nicholas S. Grasman
  • Patent number: 9693961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 4, 2017
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 9693962
    Abstract: A dry-coated tablet 1 comprises an inner core 2 which contains an active component and an outer layer 3 which contains powdery solid components and coats the inner core 2. Openings 8c and 9c are formed in circular surfaces 2a and 2b respectively of the inner core 2, wherein each of the openings is larger than the average particle size of a component the average particle size of which is the smallest of the powdery solid components contained in the outer layer 3, and the inner surface 3a of the outer layer 3 penetrates in the openings 8c and 9c.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 4, 2017
    Assignee: Takeda Pharmaceutical Limited
    Inventor: Tetsuya Kawano
  • Patent number: 9693963
    Abstract: Disclosed is a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2?,6,6?-tetraisopropyl-4,4?-biphenol, a solvent, and an antioxidant, among others.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: July 4, 2017
    Assignee: Xi'an Libang Pharmaceutical Co., Ltd.
    Inventors: Rutao Wang, Long An, Huijing Hu, Shupan Guo, Tao Chen, Weijiao Wang
  • Patent number: 9693964
    Abstract: This present invention discloses hydroxypropyl starch vacant capsules and a process for producing them, wherein said hydroxypropyl starch vacant capsules are made of hydroxypropyl starch and water and optional light-screening agent, colorant, aromatics, and flavoring agent through the processes of raw material mixup, gelatinization, stabilization, and capsule-forming. The hydroxypropyl starch capsules disclosed in this invention have such advantages as extensive source of raw material, high safety level, disintegrating property and friability over the products prepared through existing technologies.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: July 4, 2017
    Assignee: Hunan Er-Kang Pharmaceutical Co., Ltd.
    Inventors: Fangwen Shuai, Xiangfeng Wang, Jiawei Zhang
  • Patent number: 9693965
    Abstract: Provided are functional drug-containing particles which can be compressed into tablets and in particular, to orally disintegrating tablets by employing any of a dry molding method, a wet molding method, or a humidifying drying method. The functional drug-containing particles comprise substantially spherical drug-containing particles essentially including drug and a binder, the functional drug-containing particles including a functional polymer film selected from the group consisting of an enteric film, a release control film, and a bitter taste masking film, an average particle diameter of said functional drug-containing particles being 400 ?m or less, a particle diameter ratio D90/D10 of the functional drug-containing particles with respect to particle size distribution calculated on a volumetric basis being 1.65 or more, or a coefficient of variation in particle diameters being 24% or more.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: July 4, 2017
    Assignees: POWEREX CORPORATION, ZENSEI PHARMACUETICAL INDUSTRIES CO., LTD.
    Inventors: Tomohiro Hayashida, Junji Yamazaki, Yoshio Nakano, Masaya Hizaki, Naotoshi Kinoshita
  • Patent number: 9693966
    Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventor: Nachiappan Chidambaram
  • Patent number: 9693967
    Abstract: This invention is directed to an apparatus and method for producing microparticles comprising pharmacologically active agents and biodegradable polymers. The apparatus includes a spinning disk containing a reservoir in the center thereof and a flat inclined surface. The apparatus optionally includes serrations and/or a flat surface beneath the periphery of the disk that is parallel to the rotational axis of the disk. The invention is also directed to a method for producing microparticles containing pharmacologically active agents, using the spinning disk apparatus. Formulations containing ophthalmically active agents are provided. Formulations exhibiting zero order release rates are also described.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: July 4, 2017
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Joseph T. Persyn, Joseph A. McDonough, Neal K. Vail, Darren E. Barlow, Albert M. Zwiener, Eliot M. Slovin
  • Patent number: 9693968
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 4, 2017
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrencee Mielnicki, Julie Hughes
  • Patent number: 9693969
    Abstract: The present invention provides methods of administering an active agent to a specifically identified area of mucous membrane of a human being, as well as a body dissolving film formed therefore.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: July 4, 2017
    Inventor: Andrew L. Skigen
  • Patent number: 9693970
    Abstract: The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 4, 2017
    Assignee: NAL PHARMACEUTICALS GROUP LIMITED
    Inventor: Y. Joseph Mo
  • Patent number: 9693971
    Abstract: Provided are feed supplements for the alleviation of gastrointestinal tract disorders and associated systemic disorders in ruminants, methods for producing feed supplements and feeds and feed additives containing such feed supplements. Furthermore, medicaments for the treatment of diseases which are associated with disorders of the gastrointestinal tract, particularly rumen acidosis and parturient paresis, are specified.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: July 4, 2017
    Assignee: FREIE UNIVERSITÄT BERLIN
    Inventors: Friederike Stumpff, Julia Rosendahl, Jörg Aschenbach
  • Patent number: 9693972
    Abstract: Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: July 4, 2017
    Assignee: COLONARYCONCEPTS LLC
    Inventors: Michael Allio, Jonathan Gordon
  • Patent number: 9693973
    Abstract: Disclosed is a method for the treatment or prophylaxis of an inflammatory skin condition with cosmetic or pharmaceutical preparation which comprises licochalcone A and phenoxyethanol.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 4, 2017
    Assignee: BEIERSDORF AG
    Inventors: Inge Kruse, Thomas Raschke, Jens-Peter Vietzke, Julia Eckert
  • Patent number: 9693974
    Abstract: The invention relates to the use of a substance of the general form (I) to produce an antibacterial and/or antifungal drug, wherein X is a methylene group or a carbonyl group; R1, R2, and R3 are each selected from the group comprising hydrogen, an alkyl group having a chain length of 1-4 carbon atoms, an alkoxy group having a chain length of 1-3 carbon atoms, and a halogen; R4 and R5 are each selected from the group comprising hydrogen and an alkyl group having a chain length of 1-4 carbon atoms; and n=3 to 6.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 4, 2017
    Assignee: CHRISTIAN-ALBRECHTS-UNIVERSITY OF KIEL
    Inventors: Bernd Clement, Franz Furkert, Britta Gerig, Dieter Heber
  • Patent number: 9693975
    Abstract: Analgesic compounds for treatment of pain or fever, comprising a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering the compounds.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: July 4, 2017
    Assignee: Kalyra Pharmaceuticals, Inc.
    Inventor: Kevin Duane Bunker
  • Patent number: 9693976
    Abstract: Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: July 4, 2017
    Assignee: Crescita Therapeutics Inc.
    Inventor: Jie Zhang
  • Patent number: 9693977
    Abstract: Disclosed herein are compositions and methods that are useful for inducing the development of regulatory T cells (Treg). Such compositions and methods are useful for treating inflammatory conditions and in particular inflammatory conditions affecting the gastrointestinal tract of a subject. In certain embodiments, the present inventions generally relate to short chain fatty acids and the discovery that such short chain fatty acids may be used to treat and/or prevent inflammatory conditions by enhancing the size and immune function of a subject's endogenous Treg population.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: July 4, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Wendy S. Garrett, Patrick M. Smith
  • Patent number: 9693978
    Abstract: Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel Fatmi
  • Patent number: 9693979
    Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventors: Nachiappan Chidambaram, Aqeel A Fatmi
  • Patent number: 9693980
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: July 4, 2017
    Assignee: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Wilson Caparros-Wanderley, Gregory Alan Stoloff, Suzanne Jane Dilly, Gemma Szucs, Olga Pleguezuelos Mateo
  • Patent number: 9693981
    Abstract: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: July 4, 2017
    Assignee: INTEC PHARMA LTD.
    Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
  • Patent number: 9693982
    Abstract: The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 4, 2017
    Assignee: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Masako Doi, Masuhiro Nishimura, Nozomi Tamura
  • Patent number: 9693983
    Abstract: Use of glyceryl trinitrate (GTN) for treating traumatic edemas.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: July 4, 2017
    Assignee: G. Pohl-Boskamp GmbH & Co. KG
    Inventor: Marianne Boskamp
  • Patent number: 9693984
    Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: July 4, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Paresh Soni
  • Patent number: 9693985
    Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 4, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Paresh Soni
  • Patent number: 9693986
    Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: July 4, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Paresh Soni
  • Patent number: 9693987
    Abstract: Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: July 4, 2017
    Assignee: Celgene Corporation
    Inventors: Kyle J. MacBeth, Aaron N. Nguyen, Jorge Dimartino
  • Patent number: 9693988
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following, application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 4, 2017
    Assignee: DOW PHARMACEUTICAL SCIENCES, INC.
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 9693989
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: July 4, 2017
    Assignee: Array Biopharma, Inc.
    Inventors: Joseph P. Lyssikatos, Julie Marie Hicks, Fredrik P. Marmsater, Qian Zhao
  • Patent number: 9693990
    Abstract: Rhodamine dye is delivered to regions of a lung having heterogeneous alveolar flooding by alveolar liquid, thereby lowering the surface tension of the alveolar liquid so as to lessen ventilation injury directly and, by promoting equitable redistribution of the alveolar liquid among the alveoli of the lung, indirectly. The rhodamine dye is delivered with an albumin and/or an exogenous surfactant. Exemplary rhodamine dyes include sulforhodamine B and rhodamine WT.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 4, 2017
    Assignee: The Trustees of the Stevens Institute of Technology
    Inventor: Carrie E. Perlman
  • Patent number: 9693991
    Abstract: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: July 4, 2017
    Inventors: Jeffrey J. Zachwieja, Mark Arthur Pirner, JohnEric William Smith
  • Patent number: 9693992
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: July 4, 2017
    Assignee: MannKind Corporation
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • Patent number: 9693993
    Abstract: The subject invention describes a method of use of Rotigotine™ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Rotigotine as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. The use of Rotigotine provides a useful new method for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: July 4, 2017
    Inventor: Robert L. Knobler
  • Patent number: 9693994
    Abstract: In some aspects, methods for treating a bacterial infection in a mammalian subject are provided. In some embodiments, a class IIa HDAC inhibitor such as, e.g., a HDAC4 inhibitor, may be used to treat a bacterial infection such as, e.g., anthrax, pertussis, tuberculosis, or cholera.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: July 4, 2017
    Assignee: Research Development Foundation
    Inventor: Marc Montminy
  • Patent number: 9693995
    Abstract: The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid: or pharmaceutically acceptable salts thereof; and to methods of treating inflammation comprising topical administration of a compositions comprising a compound of formula I.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: July 4, 2017
    Assignee: Ziarco Pharma Limited
    Inventors: Wai Leung Liu, Lynn Purkins, Michael Yeadon
  • Patent number: 9693996
    Abstract: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: July 4, 2017
    Assignee: MARUHA NICHIRO CORPORATION
    Inventors: Hisashi Yoshioka, Akira Kamata, Tatsuya Konishi, Hiroshi Oda, Tadakazu Tamai
  • Patent number: 9693997
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: July 4, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joseph Anthony Bilotta, Zhi Chen, Feng Chi, Elbert Chin, Qingjie Ding, Shawn David Erickson, Stephen Deems Gabriel, Nan Jiang, Buelent Kocer, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert, Jing Zhang, Qiang Zhang
  • Patent number: 9693998
    Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 4, 2017
    Assignees: Cumberland Pharmaceuticals, Inc., Vanderbilt University
    Inventors: Leo Pavliv, Bryan Voss, James West, Erica Carrier
  • Patent number: 9693999
    Abstract: Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: July 4, 2017
    Assignees: University of Rochester, Board of Regents of the University of Nebraska, Temple University—Of the Commonwealth System of Higher Education
    Inventors: Paul M. Dunman, Patrick D. Olson, Wayne Childers
  • Patent number: 9694000
    Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: July 4, 2017
    Assignee: AHR PHARMACEUTICALS, INC.
    Inventor: Jiasheng Song